{"id":498110,"date":"2025-10-29T17:12:15","date_gmt":"2025-10-29T17:12:15","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/498110\/"},"modified":"2025-10-29T17:12:15","modified_gmt":"2025-10-29T17:12:15","slug":"des-chercheurs-obtiennent-des-resultats-inattendus-en-combinant-deux-medicaments","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/498110\/","title":{"rendered":"Des chercheurs obtiennent des r\u00e9sultats inattendus en combinant deux m\u00e9dicaments"},"content":{"rendered":"<p>Un <a href=\"https:\/\/www.20minutes.fr\/dossier\/traitement\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">traitement<\/a>\u00a0m\u00ealant deux m\u00e9dicaments d\u00e9j\u00e0 existants pourrait consid\u00e9rablement r\u00e9duire le risque de <a href=\"https:\/\/www.20minutes.fr\/dossier\/deces\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">d\u00e9c\u00e8s<\/a> li\u00e9 \u00e0 un <a href=\"https:\/\/www.20minutes.fr\/dossier\/cancer\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">cancer<\/a> de la <a href=\"https:\/\/www.20minutes.fr\/dossier\/prostate\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">prostate<\/a>. C\u2019est le r\u00e9sultat d\u2019une <a href=\"https:\/\/www.20minutes.fr\/dossier\/etude\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">\u00e9tude<\/a> men\u00e9e pendant huit ans par le centre Cedai-Sinar Cancer de\u00a0Los Angeles (<a href=\"https:\/\/www.20minutes.fr\/monde\/etats-unis\/\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">\u00c9tats-Unis<\/a>), rapporte <a href=\"https:\/\/newatlas.com\/cancer\/prostate-cancer-drug-combo\/\" target=\"_blank\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\">New Atlas<\/a>.<\/p>\n<p>Environ 40\u00a0% des hommes trait\u00e9s sont victimes de r\u00e9cidive, avec des chances de survie r\u00e9duites. \u00ab\u00a0Apr\u00e8s un premier traitement, certains patients voient leur cancer de la prostate revenir de mani\u00e8re agressive et risquent que la <a href=\"https:\/\/www.20minutes.fr\/dossier\/maladie\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">maladie<\/a> se propage rapidement\u00a0\u00bb, explique un des coauteurs de l\u2019\u00e9tude.<\/p>\n<p>De bien meilleures chances de survie<\/p>\n<p>L\u2019\u00e9tude a \u00e9t\u00e9 men\u00e9e sur plus de 1.000 personnes venant de 17 pays diff\u00e9rents, avec l\u2019objectif de trouver une mani\u00e8re de limiter les risques de d\u00e9c\u00e8s. Les participants ont \u00e9t\u00e9 divis\u00e9s entre trois groupes. Le premier a \u00e9t\u00e9 trait\u00e9 avec de\u00a0l\u2019enzalutamide et\u00a0le deuxi\u00e8me avec du leuprolide, deux <a href=\"https:\/\/www.20minutes.fr\/dossier\/medicament\" class=\"c-link c-link--is-underlined\" rel=\"nofollow noopener\" target=\"_blank\">m\u00e9dicaments<\/a> d\u00e9j\u00e0 prescrits pour un cancer de la prostate.<\/p>\n<p>Les participants du troisi\u00e8me groupe ont pris les deux m\u00e9dicaments en simultan\u00e9. Si aucune am\u00e9lioration n\u2019a \u00e9t\u00e9 not\u00e9e pour les deux premiers groupes, le taux de survie dans le troisi\u00e8me groupe a augment\u00e9 de 40,3\u00a0% apr\u00e8s un suivi moyen de 8 ans. Un r\u00e9sultat qui donne beaucoup d\u2019espoir aux chercheurs.<\/p>\n<\/p>\n<p>Les deux m\u00e9dicaments en question ont d\u00e9j\u00e0 \u00e9t\u00e9 approuv\u00e9s par\u00a0la\u00a0Food and Drug Administration aux \u00c9tats-Unis. Gr\u00e2ce aux r\u00e9sultats de cette \u00e9tude, l\u2019utilisation de\u00a0l\u2019enzalutamide et\u00a0leuprolide de mani\u00e8re combin\u00e9e pourrait donc \u00eatre rapidement autoris\u00e9e afin d\u2019am\u00e9liorer les chances de survie de tous les patients concern\u00e9s.<\/p>\n","protected":false},"excerpt":{"rendered":"Un traitement\u00a0m\u00ealant deux m\u00e9dicaments d\u00e9j\u00e0 existants pourrait consid\u00e9rablement r\u00e9duire le risque de d\u00e9c\u00e8s li\u00e9 \u00e0 un cancer de&hellip;\n","protected":false},"author":2,"featured_media":498111,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[47,101,7079,73,7078,1011,27,72,225,23178,71,227],"class_list":{"0":"post-498110","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-actualite","9":"tag-cancer","10":"tag-chercheurs","11":"tag-etats-unis","12":"tag-etude","13":"tag-fr","14":"tag-france","15":"tag-health","16":"tag-medicament","17":"tag-prostate","18":"tag-sante","19":"tag-traitement"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115458575291968884","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/498110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=498110"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/498110\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/498111"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=498110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=498110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=498110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}